Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
10.5 mg budesonide effervescent tablet for orodispersible use[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
21 mg budesonide effervescent tablet for orodispersible use[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
31mg budesonide effervescent tablet for orodispersible use[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
42mg budesonide effervescent tablet for orodispersible use[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
55 mg Montelukast[1] Montelukast[1] Montelukast 💬[1] CYSLTR1 💬[2] Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬[1] 98 💬
6AK002----[1] 98 💬
7Allergy immunotherapy (allergy shots)----[1] 98 💬
8Alpha-proteinase inhibitor----[1] 98 💬
9AMG 157[1] Tezepelumab[1] Tezepelumab 💬[1] TSLP 💬[2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬[1] 98 💬
10AMG157----[1] 98 💬
11APD334----[5] 93, 96, 97, 98, 269 💬
12APT-1011----[1] 98 💬
13APT-1011 - 3 mg----[1] 98 💬
14APT-1011 3 mg HS----[1] 98 💬
15AQ280----[1] 98 💬
16AR401959 L-arginine[2] Arginine,
L-arginine		[1] Arginine 💬--[3] 96, 97, 98 💬
17Arginine[1] Arginine[1] Arginine 💬--[11] 46, 58, 67, 78, 96, 97, 98, 113, 210, 251, 299 💬
18Baked Milk[1] Cow milk---[1] 98 💬
19Barzolvolimab----[1] 98 💬
20Beclomethasone dipropionate[1] Beclomethasone dipropionate[1] Beclomethasone dipropionate 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 97, 98 💬
21Benralizumab[1] Benralizumab[1] Benralizumab 💬[1] IL5RA 💬[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬[5] 44, 45, 98, 162, 299 💬
22Bethanechol[1] Bethanechol---[1] 98 💬
23BT----[3] 96, 97, 98 💬
24BT-11 1000mg----[3] 96, 97, 98 💬
25BT-11 500mg----[1] 98 💬
26BUDESONIDE[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[9] 66, 93, 94, 95, 96, 97, 98, 228, 299 💬
27Budesonide 0.5 mg compresse orodispersibili[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
28Budesonide 0.5 mg orodispersible tablets[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
29Budesonide 0.5mg orodispersible tablet twice daily[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
30Budesonide 1 mg compresse orodispersibili[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
31Budesonide 1 mg orodispersible tablets[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
32Budesonide 1 mg orodispersible tablets (BUL 1 mg)[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
33Budesonide 1mg orodispersible tablet twice daily[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
34Budesonide 2 mg orodispersible tablets (BUL 2 mg)[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
35Budesonide [0.4mg/ml] viscous suspension[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
36Budesonide Gel[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
37Budesonide oral suspension[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
38Budesonide oral suspension [0.2 mg/ml][1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
39Budesonide Orodispersible Tablets (Jorveza)[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
40Budesonide plus Prevacid[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
41BUET 0.5 mg----[1] 98 💬
42BUET 1 mg----[1] 98 💬
43BUET 1mg----[1] 98 💬
44BUET 2mg----[1] 98 💬
45BUL 0.5 mg----[1] 98 💬
46BUL 1 mg----[1] 98 💬
47BUU 0.4mg/ml----[1] 98 💬
48CALY-002----[1] 98 💬
49CC----[13] 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271 💬
50CC-93538----[1] 98 💬
51Cendakimab----[1] 98 💬
52Citalopram[1] Citalopram[1] Citalopram 💬[1] SLC6A4 💬[2] Serotonergic synapse, Synaptic vesicle cycle 💬[7] 6, 8, 13, 18, 46, 98, 127 💬
53Compressa effervescente 0,5 mg di budesonide per uso orodispersibile[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
54Compressa effervescente 1 mg di budesonide per uso orodispersibile[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
55Cromolyn[1] Cromoglicic acid[1] Cromoglicic acid 💬--[3] 2, 85, 98 💬
56CYP substrates----[1] 98 💬
57Dexlansoprazole[1] Dexlansoprazole[1] Dexlansoprazole 💬[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[1] 98 💬
58Dupilumab[1] Dupilumab[1] Dupilumab 💬[1] IL4R 💬[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[5] 51, 97, 98, 160, 162 💬
59Dupilumab (blinded)[1] Dupilumab[1] Dupilumab 💬[1] IL4R 💬[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 98 💬
60Dupilumab (open-label)[1] Dupilumab[1] Dupilumab 💬[1] IL4R 💬[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 98 💬
61Dupixent[1] Dupilumab[1] Dupilumab 💬[1] IL4R 💬[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[3] 98, 160, 162 💬
62Else nutrition formula----[1] 98 💬
63Eosinophilic Esophagitis (E0E) food introduction-2nd----[1] 98 💬
64Eosinophilic Esophagitis (EoE) food introduction-1st----[1] 98 💬
65Eosinophilic Esophagitis (EoE) Food introduction-3rd dose----[1] 98 💬
66EP-104IAR----[1] 98 💬
67ESO-101----[1] 98 💬
68Esomeprazole[1] Esomeprazole[1] Esomeprazole 💬[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[8] 13, 46, 86, 98, 107, 113, 298, 299 💬
69Etrasimod[1] Etrasimod[1] Etrasimod 💬[5] S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬[3] 96, 97, 98 💬
70Etrasimod L-arginine[3] Arginine,
Etrasimod,
L-arginine		[2] Arginine ,
Etrasimod 💬		[5] S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬[3] 96, 97, 98 💬
71EUR-1100----[1] 98 💬
72Famotidine[1] Famotidine[1] Famotidine 💬[1] HRH2 💬[3] Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬[5] 6, 46, 86, 98, 107 💬
73Fasenra[1] Benralizumab[1] Benralizumab 💬[1] IL5RA 💬[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬[5] 44, 45, 98, 162, 299 💬
74Florence 30 µg/mL----[1] 98 💬
75Florence 60 µg/mL----[1] 98 💬
76Florence 90 µg/mL----[1] 98 💬
77Flovent----[1] 98 💬
78Fluticasone[2] Fluticasone,
Fluticasone propionate		[2] Fluticasone propionate ,
Fluticasone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[3] 98, 228, 299 💬
79Fluticasone MDI[1] Fluticasone[1] Fluticasone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
80FLUTICASONE PROPIONATE[2] Fluticasone,
Fluticasone propionate		[2] Fluticasone propionate ,
Fluticasone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 98, 228 💬
81Fluticasone Propionate, USP[2] Fluticasone,
Fluticasone propionate		[2] Fluticasone propionate ,
Fluticasone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
82Gold[1] Gold---[43] 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318 💬
83High dose budesonide suspension[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
84High dose budesonide tablet[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
85Infliximab[1] Infliximab[1] Infliximab 💬[1] TNF 💬[67] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[26] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
86Inhaled/swallowed budesonide[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
87Intubated with Propofol (IP)[1] Propofol[1] Propofol 💬[16] GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬[1] 98 💬
88Intubated with Sevoflurane (IS)[1] Sevoflurane[1] Sevoflurane 💬--[1] 98 💬
89IRL201104----[1] 98 💬
90Jorveza[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
91Jorveza 0.5 mg compresse orodispersibili[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
92Jorveza 0.5 mg orodispersible tablets[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
93Jorveza 1 mg compresse orodispersibili[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
94Jorveza 1 mg orodispersible tablets[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
95L-arginine[2] Arginine,
L-arginine		[1] Arginine 💬--[8] 46, 67, 78, 96, 97, 98, 113, 299 💬
96Lansoprazole[1] Lansoprazole[1] Lansoprazole 💬[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[7] 63, 71, 85, 98, 166, 222, 299 💬
97Lirentelimab[1] Lirentelimab[1] Lirentelimab 💬[1] SIGLEC8 💬-[1] 98 💬
98Lirentelimab (AK002)[1] Lirentelimab[1] Lirentelimab 💬[1] SIGLEC8 💬-[1] 98 💬
99Loratadine[1] Loratadine[1] Loratadine 💬[1] HRH1 💬[3] Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬[4] 13, 46, 89, 98 💬
100Losartan[1] Losartan[1] Losartan 💬[1] AGTR1 💬[16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[17] 17, 19, 36, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬
101LOSARTAN POTASSIUM[2] Losartan,
Potassium		[2] Losartan ,
Potassium 💬		[1] AGTR1 💬[16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[5] 36, 98, 167, 179, 215 💬
102Low dose budesonide tablet[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
103MEDI-563----[5] 44, 45, 98, 162, 299 💬
104MEDI9929[1] Tezepelumab[1] Tezepelumab 💬[1] TSLP 💬[2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬[1] 98 💬
105MEDI9929 anti-TSLP mAb (AMG157)[1] Tezepelumab[1] Tezepelumab 💬[1] TSLP 💬[2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬[1] 98 💬
106MEPOLIZUMAB[1] Mepolizumab[1] Mepolizumab 💬[1] IL5 💬[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[4] 44, 45, 98, 162 💬
107Mepolizumab 100 mg[1] Mepolizumab[1] Mepolizumab 💬[1] IL5 💬[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 98 💬
108Mepolizumab 300 mg[1] Mepolizumab[1] Mepolizumab 💬[1] IL5 💬[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 98 💬
109Mesalamine[1] Mesalazine[1] Mesalamine 💬--[4] 96, 97, 98, 164 💬
110Mesalamine Oral Product[1] Mesalazine[1] Mesalamine 💬--[1] 98 💬
111Milk[1] Cow milk---[1] 98 💬
112Mometasone[2] Mometasone,
Mometasone furoate		[2] Mometasone furoate ,
Mometasone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 98, 162 💬
113MOMETASONE FUROATE[2] Mometasone,
Mometasone furoate		[2] Mometasone furoate ,
Mometasone 💬		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 98, 162 💬
114Montelukast[1] Montelukast[1] Montelukast 💬[1] CYSLTR1 💬[2] Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬[8] 6, 13, 46, 61, 63, 85, 98, 228 💬
115Montelukast/ Singulair[1] Montelukast[1] Montelukast 💬[1] CYSLTR1 💬[2] Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬[1] 98 💬
116Nasonex----[1] 98 💬
117OC000459----[1] 98 💬
118OMALIZUMAB[1] Omalizumab[1] Omalizumab 💬[1] FCER1A 💬[4] Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬[7] 46, 53, 65, 98, 162, 226, 299 💬
119Oral Budesonide[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
120Oral Budesonide Suspension (MB-9)[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
121Oral Budesonide Suspension (OBS)[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
122Oral cromolyn sodium[1] Cromoglicic acid[1] Cromoglicic acid 💬--[1] 98 💬
123Oral Viscous Budesonide[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
124Oral Viscous Budesonide (OVB)[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
125Picoprep----[1] 98 💬
126Potassium[1] Potassium[1] Potassium 💬--[13] 36, 46, 66, 67, 88, 93, 94, 98, 115, 167, 179, 215, 235 💬
127PROPOFOL[1] Propofol[1] Propofol 💬[16] GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬[8] 6, 21, 22, 34, 46, 70, 98, 296 💬
128QAX576----[4] 51, 85, 96, 98 💬
129Reslizumab[1] Reslizumab[1] Reslizumab 💬[1] IL5 💬[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 98 💬
130RPC4046----[1] 98 💬
131SB-240563----[3] 44, 45, 98 💬
132SCH55700----[1] 98 💬
133Sevoflurane[1] Sevoflurane[1] Sevoflurane 💬--[7] 6, 21, 22, 34, 98, 225, 296 💬
134Sirolimus[1] Sirolimus[1] Sirolimus 💬[1] MTOR 💬[51] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬[35] 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 300, 331 💬
135Steroid and Proton Pump Inhibitor Therapy----[1] 98 💬
136Sucralfate[1] Sucralfate[1] Sucralfate 💬--[1] 98 💬
137Swallowed fluticasone[1] Fluticasone[1] Fluticasone 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
138Tezepelumab[1] Tezepelumab[1] Tezepelumab 💬[1] TSLP 💬[2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬[1] 98 💬
139Tezepelumab via APFS[1] Tezepelumab[1] Tezepelumab 💬[1] TSLP 💬[2] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬[1] 98 💬
140Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms[1] Lansoprazole[1] Lansoprazole 💬[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[1] 98 💬
141Viaskin Milk 500 mcg[1] Cow milk---[1] 98 💬
142Viscous/swallowed budesonide[1] Budesonide[1] Budesonide 💬[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98 💬
143Vonoprazan[1] Vonoprazan[1] Vonoprazan 💬[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[2] 63, 98 💬
144Zofran - no intubation----[1] 98 💬